Literature DB >> 23592770

Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.

Ann Yi1, Nariya Cho, Seock-Ah Im, Jung Min Chang, Seung Ja Kim, Hyeung-Gon Moon, Wonshik Han, In-Ae Park, Dong-Young Noh, Woo Kyung Moon.   

Abstract

PURPOSE: To retrospectively evaluate whether dynamic contrast agent-enhanced (DCE) magnetic resonance (MR) imaging parameters assessed by a computer-aided evaluation program are associated with recurrence-free and overall survival in breast cancer patients who received neoadjuvant chemotherapy (NAC).
MATERIALS AND METHODS: This study was institutional review board approved and informed consent was waived. Between January 2007 and December 2009, 187 consecutive women (mean age, 46.6 years; range, 24-78 years) who had undergone NAC, DCE MR imaging before and after NAC, and surgery for invasive breast cancers (mean size, 5.0 cm; range, 2.0-14.8 cm on surgical histologic analysis) were identified. The tumor size, volume, and kinetic parameters (persistent, plateau, or washout components) were measured with a computer-aided evaluation program on DCE MR images before and after NAC, and their percentage changes were calculated. The Cox proportional hazards model was used to determine the association between DCE MR imaging parameters and recurrence-free survival and overall survival after controlling for clinical-pathologic variables.
RESULTS: There were 50 events, including 38 recurrences (29 distant, six local, and three both) and 12 deaths, at a mean follow-up of 47.4 months. At multivariate analysis, a smaller reduction in tumor volume (recurrence-free survival hazard ratio, 5.75; 95% confidence interval: 1.14, 8.64; and overall survival hazard ratio, 2.12; 95% confidence interval: 1.08, 5.69) and a smaller reduction in washout component (recurrence-free survival hazard ratio, 1.15; 95% CI: 1.06, 1.55; and overall survival hazard ratio, 1.26; 95% confidence interval: 1.03, 1.52) after NAC were independent significant variables for worse recurrence-free survival and overall survival.
CONCLUSION: Smaller reduction in tumor volume and a smaller reduction in washout component on DCE MR images assessed with computer-aided evaluation after NAC were independent parameters of worse recurrence-free survival and overall survival in breast cancer patients who received NAC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23592770     DOI: 10.1148/radiol.13121801

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  18 in total

1.  Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer.

Authors:  Jia Wu; Bailiang Li; Xiaoli Sun; Guohong Cao; Daniel L Rubin; Sandy Napel; Debra M Ikeda; Allison W Kurian; Ruijiang Li
Journal:  Radiology       Date:  2017-07-14       Impact factor: 11.105

2.  Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators.

Authors:  Martin D Pickles; Martin Lowry; David J Manton; Lindsay W Turnbull
Journal:  Eur Radiol       Date:  2014-11-26       Impact factor: 5.315

3.  Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.

Authors:  Elizabeth J Sutton; Jung Hun Oh; Brittany Z Dashevsky; Harini Veeraraghavan; Aditya P Apte; Sunitha B Thakur; Joseph O Deasy; Elizabeth A Morris
Journal:  J Magn Reson Imaging       Date:  2015-04-07       Impact factor: 4.813

4.  The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy.

Authors:  Ilhan Lim; Woo Chul Noh; Jihyun Park; Ji Ae Park; Hyun-Ah Kim; Eun-Kyu Kim; Ko Woon Park; Seung Sook Lee; Eun Young You; Kyeong Min Kim; Byung Hyun Byun; Byung Ii Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-14       Impact factor: 9.236

5.  Is there any correlation between model-based perfusion parameters and model-free parameters of time-signal intensity curve on dynamic contrast enhanced MRI in breast cancer patients?

Authors:  Boram Yi; Doo Kyoung Kang; Dukyong Yoon; Yong Sik Jung; Ku Sang Kim; Hyunee Yim; Tae Hee Kim
Journal:  Eur Radiol       Date:  2014-02-21       Impact factor: 5.315

6.  Prediction of pathological complete response of breast cancer patients undergoing neoadjuvant chemotherapy: usefulness of breast MRI computer-aided detection.

Authors:  H Kim; H H Kim; J S Park; H J Shin; J H Cha; E Y Chae; W J Choi
Journal:  Br J Radiol       Date:  2014-08-27       Impact factor: 3.039

7.  Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.

Authors:  Nazia F Jafri; David C Newitt; John Kornak; Laura J Esserman; Bonnie N Joe; Nola M Hylton
Journal:  J Magn Reson Imaging       Date:  2013-12-18       Impact factor: 4.813

8.  Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles.

Authors:  Ahmed Bilal Ashraf; Dania Daye; Sara Gavenonis; Carolyn Mies; Michael Feldman; Mark Rosen; Despina Kontos
Journal:  Radiology       Date:  2014-04-04       Impact factor: 11.105

9.  Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression.

Authors:  Min Sun Bae; So Yeon Park; Sung Eun Song; Won Hwa Kim; Su Hyun Lee; Wonshik Han; In-Ae Park; Dong-Young Noh; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2014-09-16       Impact factor: 5.315

10.  Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.

Authors:  Shelley A Henderson; Nazleen Muhammad Gowdh; Colin A Purdie; Lee B Jordan; Andrew Evans; Tracy Brunton; Alastair M Thompson; Sarah Vinnicombe
Journal:  Br J Radiol       Date:  2018-05-02       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.